Compare Stocks: GOSS, MOLN, IVVD, and ABOS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.26 +0.7%	$2.37	$1.19 ▼ $3.60	$162.88M	0.36	606,293 shs	179,567 shs
GOSS Gossamer Bio	$0.18 -0.3%	$0.17	$0.11 ▼ $3.87	$42.01M	2.04	18.33 million shs	5.36 million shs
IVVD Invivyd	$0.60 +5.2%	$0.85	$0.48 ▼ $3.07	$177.65M	0.71	3.57 million shs	2.74 million shs
MOLN Molecular Partners	$4.13 -0.7%	$3.97	$3.46 ▼ $5.36	$166.73M	1.08	1,597 shs	254 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	+2.75%	-1.75%	-18.25%	-12.84%	+68.42%
GOSS Gossamer Bio	+4.55%	-11.51%	+4.79%	-48.17%	-91.64%
IVVD Invivyd	+3.92%	-3.39%	-35.87%	-60.74%	-21.26%
MOLN Molecular Partners	-1.56%	+9.15%	+3.39%	-4.08%	+10.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.26 +0.7%	$2.37	$1.19 ▼ $3.60	$162.88M	0.36	606,293 shs	179,567 shs
GOSS Gossamer Bio	$0.18 -0.3%	$0.17	$0.11 ▼ $3.87	$42.01M	2.04	18.33 million shs	5.36 million shs
IVVD Invivyd	$0.60 +5.2%	$0.85	$0.48 ▼ $3.07	$177.65M	0.71	3.57 million shs	2.74 million shs
MOLN Molecular Partners	$4.13 -0.7%	$3.97	$3.46 ▼ $5.36	$166.73M	1.08	1,597 shs	254 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	+2.75%	-1.75%	-18.25%	-12.84%	+68.42%
GOSS Gossamer Bio	+4.55%	-11.51%	+4.79%	-48.17%	-91.64%
IVVD Invivyd	+3.92%	-3.39%	-35.87%	-60.74%	-21.26%
MOLN Molecular Partners	-1.56%	+9.15%	+3.39%	-4.08%	+10.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	2.33	Hold	$8.00	254.14% Upside
GOSS Gossamer Bio	2.22	Hold	$3.20	1,677.78% Upside
IVVD Invivyd	2.33	Hold	$8.00	1,291.30% Upside
MOLN Molecular Partners	2.25	Hold	$8.38	102.83% Upside

Current Analyst Ratings Breakdown

Latest GOSS, MOLN, IVVD, and ABOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$1.00
7/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	MOLN Molecular Partners	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/6/2026	ABOS Acumen Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	MOLN Molecular Partners	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/25/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00 ➝ $2.00
6/15/2026	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
6/9/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
6/1/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.16 per share	N/A
GOSS Gossamer Bio	$48.47M	0.87	N/A	N/A	($0.53) per share	-0.34
IVVD Invivyd	$53.43M	3.17	N/A	N/A	$1.04 per share	0.55
MOLN Molecular Partners	$5.65M	29.51	N/A	N/A	$2.40 per share	1.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$121.33M	-$1.86	N/A	N/A	N/A	N/A	-123.07%	-79.41%	8/11/2026 (Estimated)
GOSS Gossamer Bio	-$170.37M	-$0.79	N/A	N/A	N/A	-324.82%	N/A	-96.10%	N/A
IVVD Invivyd	-$52.49M	-$0.31	N/A	N/A	N/A	-138.90%	-53.48%	-41.56%	8/13/2026 (Estimated)
MOLN Molecular Partners	-$74.41M	-$1.94	N/A	N/A	N/A	N/A	-66.62%	-54.85%	8/25/2026 (Estimated)

Latest GOSS, MOLN, IVVD, and ABOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2026	Q2 2026	MOLN Molecular Partners	-$0.45	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	IVVD Invivyd	-$0.15	N/A	N/A	N/A	$14.40 million	N/A
8/11/2026	Q2 2026	ABOS Acumen Pharmaceuticals	-$0.39	N/A	N/A	N/A	N/A	N/A
5/15/2026	Q1 2026	GOSS Gossamer Bio	-$0.17	-$0.20	-$0.03	-$0.20	$4.67 million	$16.96 million
5/14/2026	Q1 2026	IVVD Invivyd	-$0.08	-$0.13	-$0.05	-$0.13	$18.04 million	$13.74 million
5/12/2026	Q1 2026	ABOS Acumen Pharmaceuticals	-$0.4028	-$0.33	+$0.0728	-$0.33	N/A	N/A
5/11/2026	Q1 2026	MOLN Molecular Partners	-$0.4340	-$0.45	-$0.0160	-$0.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.19	4.55	4.55
GOSS Gossamer Bio	N/A	2.20	2.20
IVVD Invivyd	N/A	6.47	6.47
MOLN Molecular Partners	N/A	9.43	9.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
GOSS Gossamer Bio	81.23%
IVVD Invivyd	70.36%
MOLN Molecular Partners	26.55%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	10.20%
GOSS Gossamer Bio	3.74%
IVVD Invivyd	12.25%
MOLN Molecular Partners	5.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	72.23 million	64.86 million	Optionable
GOSS Gossamer Bio	180	234.70 million	225.92 million	Optionable
IVVD Invivyd	100	294.61 million	258.52 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable

GOSS, MOLN, IVVD, and ABOS Headlines

Recent News About These Companies

Molecular Partners (NASDAQ:MOLN) Shares Up 6.4% - Still a Buy?

August 3 at 12:59 AM | marketbeat.com

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

July 15, 2026 | globenewswire.com

LifeSci Capital Sticks to Their Buy Rating for Molecular Partners (MOLN)

July 12, 2026 | theglobeandmail.com

Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Declines By 84.3%

July 11, 2026 | marketbeat.com

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

July 6, 2026 | globenewswire.com

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

July 2, 2026 | globenewswire.com

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

May 30, 2026 | globenewswire.com

Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit

May 26, 2026 | globenewswire.com

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

May 12, 2026 | globenewswire.com

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences

May 4, 2026 | globenewswire.com

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

May 1, 2026 | globenewswire.com

Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712

April 19, 2026 | globenewswire.com

Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting

April 14, 2026 | globenewswire.com

Molecular Partners AG Sponsored ADR

April 10, 2026 | edition.cnn.com

Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors

March 23, 2026 | globenewswire.com

Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes

March 19, 2026 | globenewswire.com

Molecular Partners to Hold Three Poster Presentations at AACR 2026

March 17, 2026 | globenewswire.com

Molecular Partners Reports Highlights and Financial Results for Full Year 2025

March 12, 2026 | globenewswire.com

Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics

February 26, 2026 | finance.yahoo.com

Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results

February 26, 2026 | globenewswire.com

Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript

February 2, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, MOLN, IVVD, and ABOS Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$2.26 +0.02 (+0.67%)

As of 03:07 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Gossamer Bio NASDAQ:GOSS

$0.18 0.00 (-0.28%)

As of 03:07 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Invivyd NASDAQ:IVVD

$0.60 +0.03 (+5.20%)

As of 03:08 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Molecular Partners NASDAQ:MOLN

$4.13 -0.03 (-0.75%)

Closing price 09:26 AM Eastern

Extended Trading

$4.13 0.00 (0.00%)

As of 09:26 AM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GOSS, MOLN, IVVD, and ABOS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GOSS, MOLN, IVVD, and ABOS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GOSS, MOLN, IVVD, and ABOS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, MOLN, IVVD, and ABOS Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Gossamer Bio NASDAQ:GOSS

Invivyd NASDAQ:IVVD

Molecular Partners NASDAQ:MOLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GOSS, MOLN, IVVD, and ABOS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GOSS, MOLN, IVVD, and ABOS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GOSS, MOLN, IVVD, and ABOS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, MOLN, IVVD, and ABOS Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Gossamer Bio NASDAQ:GOSS

Invivyd NASDAQ:IVVD

Molecular Partners NASDAQ:MOLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools